Olema Oncology (OLMA) News
NASDAQ: OLMAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.02-0.13 (-1.82%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OLMA news summary
We found 11 recent headlines mentioning Olema Oncology (OLMA): 3 in the past week and 9 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. For price context, OLMA is down 1.82% at $7.02. The most recent story, "Olema Reports Promising Early Results For New Breast Cancer Drug Candidates", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Olema Oncology headlines
- Olema Reports Promising Early Results For New Breast Cancer Drug Candidates(RTTNews) - Olema Oncology, Inc. (OLMA), a biotechnology company developing treatments for breast cancer, announced positive preclinical results for four experimental drugs designed to target a…NasdaqOLMA, BF.A
- Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR SymposiumSAN FRANCISCO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc . (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…GlobeNewswire
- Olema Oncology to Participate in Upcoming Investor ConferencesSAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…GlobeNewswire
- Commit To Purchase Olema Oncology At $5, Earn 27% Using OptionsInvestors eyeing a purchase of Olema Oncology Inc (Symbol: OLMA) shares, but tentative about paying the going market price of $7.54/share, might benefit from considering selling puts among the…Nasdaq
- Olema Oncology Announces Corporate Name ChangeSAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company…GlobeNewswire
- Olema Pharmaceuticals GAAP EPS of -$0.73 misses by $0.10Seeking Alpha
- Olema Oncology Reports Third Quarter 2026 Financial and Operating ResultsSAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,…GlobeNewswire
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,…GlobeNewswire
- Olema Oncology to Participate in Upcoming Investor ConferencesSAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,…GlobeNewswire
- The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyAstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.NasdaqAZN, PBYI, OLMA
- 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthAZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.NasdaqAZN, PBYI, OLMA